Neurology International Open 2017; 01(03): E204-E210
DOI: 10.1055/s-0043-110165
Review
© Georg Thieme Verlag KG Stuttgart · New York

The Treatment and Prognosis of Refractory and Super-Refractory Status Epilepticus

Stephanie Gollwitzer
1   Epilepsy Center, Department of Neurology, University Hospital of Erlangen, Erlangen, Germany
,
Hajo M. Hamer
1   Epilepsy Center, Department of Neurology, University Hospital of Erlangen, Erlangen, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
04 September 2017 (online)

Abstract

Refractory status epilepticus (RSE) is defined as status epilepticus (SE) persisting over 60 min and resistant to treatment with benzodiazepines and non-sedating antiepileptic drugs. The term super-refractory status epilepticus (SRSE) refers to a refractory episode continuing under general anesthesia for more than 24 h. RSE is treated with a combination of non-sedating AED and i. v. anesthetics; first choice drugs are midazolam, propofol and thiopental. The management of super-refractory status epilepticus (SRSE) is challenging as clear evidence-based guidelines are lacking. Recommendations are mainly based on case reports and small case series. Therapeutic options include ketamine, inhalational anesthetics, steroids and immunoglobulins. Ketogenic diet, electroconvulsive therapy and epilepsy surgery are also considered as potentially effective. A promising new approach is the neurosteroid allopregnanolone. Mortality of RSE and SRSE is largely influenced by the etiology and is markedly higher as compared to non-refractory status epilepticus. It was reported to be about 30% and 50%, respectively.

 
  • References

  • 1 Knake S, Rosenow F, Vescovi M. et al. Incidence of status epilepticus in adults in Germany: A prospective, population-based study. Epilepsia 2001; 42: 714-718
  • 2 Delaj L, Novy J, Ryvlin P. et al. Refractory and super-refractory status epilepticus in adults: A 9-year cohort study. Acta Neurol Scand 2017; 135: 92-99
  • 3 Trinka E, Cock H, Hesdorffer D. et al. A definition and classification of status epilepticus–Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015; 56: 1515-1523
  • 4 Dobesberger J, Ristic AJ, Walser G. et al. Duration of focal complex, secondarily generalized tonic-clonic, and primarily generalized tonic-clonic seizures–A video-EEG analysis. Epilepsy Behav 2015; 49: 111-117
  • 5 Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: A critical review of available therapies and a clinical treatment protocol. Brain 2011; 134: 2802-2818
  • 6 Mayer SA, Claassen J, Lokin J. et al. Refractory status epilepticus: Frequency, risk factors, and impact on outcome. Arch Neurol 2002; 59: 205-210
  • 7 Holtkamp M, Othman J, Buchheim K. et al. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry 2005; 76: 534-539
  • 8 Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: Effect of treatment aggressiveness on prognosis. Arch Neurol 2005; 62: 1698-1702
  • 9 Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: A prospective observational study. Epilepsia 2010; 51: 251-256
  • 10 Wilder-Smith EP, Lim EC, Teoh HL. et al. The NORSE (new-onset refractory status epilepticus) syndrome: Defining a disease entity. Ann Acad Med Singapore 2005; 34: 417-420
  • 11 Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain 2012; 135: 2314-2328
  • 12 Loscher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: Experimental approaches and translational research. Pharmacol Rev 2010; 62: 668-700
  • 13 Claassen J, Hirsch LJ, Emerson RG. et al. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: A systematic review. Epilepsia 2002; 43: 146-153
  • 14 Rossetti AO, Milligan TA, Vulliemoz S. et al. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care 2011; 14: 4-10
  • 15 Prabhakar H, Bindra A, Singh GP. et al. Propofol versus thiopental sodium for the treatment of refractory status epilepticus. Cochrane Database Syst Rev 2012; DOI: 10.1002/14651858.CD009202.pub2. CD009202
  • 16 Reznik ME, Berger K, Claassen J. Comparison of Intravenous Anesthetic Agents for the Treatment of Refractory Status Epilepticus. J Clin Med 2016; 5:
  • 17 Pugin D, Foreman B, De Marchis GM. et al. Is pentobarbital safe and efficacious in the treatment of super-refractory status epilepticus: A cohort study. Crit Care 2014; 18: R103
  • 18 Bellante F, Legros B, Depondt C. et al. Midazolam and thiopental for the treatment of refractory status epilepticus: A retrospective comparison of efficacy and safety. J Neurol 2016; 263: 799-806
  • 19 Walli A, Poulsen TD, Dam M. et al. Propofol infusion syndrome in refractory status epilepticus: A case report and topical review. Case Rep Emerg Med 2016 2016: 3265929
  • 20 Power KN, Flaatten H, Gilhus NE. et al. Propofol treatment in adult refractory status epilepticus. Mortality risk and outcome. Epilepsy Res 2011; 94: 53-60
  • 21 Morrison G, Gibbons E, Whitehouse WP. High-dose midazolam therapy for refractory status epilepticus in children. Intensive Care Med 2006; 32: 2070-2076
  • 22 Young GB. Status epilepticus and brain damage: Pathology and pathophysiology. Adv Neurol 2006; 97: 217-220
  • 23 Rossetti AO, Hurwitz S, Logroscino G. et al. Prognosis of status epilepticus: Role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry 2006; 77: 611-615
  • 24 Marchi NA, Novy J, Faouzi M. et al. Status epilepticus: Impact of therapeutic coma on outcome. Crit Care Med 2015; 43: 1003-1009
  • 25 Sutter R, Marsch S, Fuhr P. et al. Anesthetic drugs in status epilepticus: Risk or rescue? A 6-year cohort study. Neurology 2014; 82: 656-664
  • 26 Sutter R, De Marchis GM, Semmlack S. et al. Anesthetics and outcome in status epilepticus: A matched two-center cohort study. CNS Drugs 2017; 31: 65-74
  • 27 Towne AR, Waterhouse EJ, Boggs JG. et al. Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology 2000; 54: 340-345
  • 28 Claassen J, Mayer SA, Kowalski RG. et al. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology 2004; 62: 1743-1748
  • 29 Spatola M, Novy J, Du Pasquier R. et al. Status epilepticus of inflammatory etiology: A cohort study. Neurology 2015; 85: 464-470
  • 30 Gaspard N, Foreman BP, Alvarez V. et al. New-onset refractory status epilepticus: Etiology, clinical features, and outcome. Neurology 2015; 85: 1604-1613
  • 31 Tan RY, Neligan A, Shorvon SD. The uncommon causes of status epilepticus: A systematic review. Epilepsy Res 2010; 91: 111-122
  • 32 Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology 1993; 43: 483-488
  • 33 Borris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res 2000; 42: 117-122
  • 34 Gaspard N, Foreman B, Judd LM. et al. Intravenous ketamine for the treatment of refractory status epilepticus: A retrospective multicenter study. Epilepsia 2013; 54: 1498-1503
  • 35 Mirsattari SM, Sharpe MD, Young GB. Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. Arch Neurol 2004; 61: 1254-1259
  • 36 Vezzani A, Ruegg S. The pivotal role of immunity and inflammatory processes in epilepsy is increasingly recognized: Introduction. Epilepsia 2011; 52 (Suppl. 03) 1-4
  • 37 Zeiler FA, Matuszczak M, Teitelbaum J. et al. Plasmapheresis for refractory status epilepticus, part I: A scoping systematic review of the adult literature. Seizure 2016; 43: 14-22
  • 38 Francois LL, Manel V, Rousselle C. et al. Ketogenic regime as anti-epileptic treatment: Its use in 29 epileptic children. Arch Pediatr 2003; 10: 300-306
  • 39 Thakur KT, Probasco JC, Hocker SE. et al. Ketogenic diet for adults in super-refractory status epilepticus. Neurology 2014; 82: 665-670
  • 40 Strzelczyk A, Reif PS, Bauer S. et al. Intravenous initiation and maintenance of ketogenic diet: Proof of concept in super-refractory status epilepticus. Seizure 2013; 22: 581-583
  • 41 Legriel S, Lemiale V, Schenck M. et al. Hypothermia for Neuroprotection in Convulsive Status Epilepticus. N Engl J Med 2016; 375: 2457-2467
  • 42 Niquet J, Gezalian M, Baldwin R. et al. Neuroprotective effects of deep hypothermia in refractory status epilepticus. Ann Clin Transl Neurol 2015; 2: 1105-1115
  • 43 Niquet J, Baldwin R, Gezalian M. et al. Deep hypothermia for the treatment of refractory status epilepticus. Epilepsy Behav 2015; 49: 313-317
  • 44 Lhatoo SD, Alexopoulos AV. The surgical treatment of status epilepticus. Epilepsia 2007; 48 (Suppl. 08) 61-65
  • 45 Lisanby SH, Bazil CW, Resor SR. et al. ECT in the treatment of status epilepticus. J ECT 2001; 17: 210-215
  • 46 Griesemer DA, Kellner CH, Beale MD. et al. Electroconvulsive therapy for treatment of intractable seizures. Initial findings in two children. Neurology 1997; 49: 1389-1392
  • 47 Broomall E, Natale JE, Grimason M. et al. Pediatric super-refractory status epilepticus treated with allopregnanolone. Ann Neurol 2014; 76: 911-915
  • 48 Kokate TG, Cohen AL, Karp E. et al. Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice. Neuropharmacology 1996; 35: 1049-1056
  • 49 Reddy K, Reife R, Cole AJ. SGE-102: A novel therapy for refractory status epilepticus. Epilepsia 2013; 54 (Suppl. 06) 81-83
  • 50 Towne AR, Pellock JM, Ko D. et al. Determinants of mortality in status epilepticus. Epilepsia 1994; 35: 27-34
  • 51 Neligan A, Shorvon SD. Prognostic factors, morbidity and mortality in tonic-clonic status epilepticus: A review. Epilepsy Res 2011; 93: 1-10
  • 52 Rossetti AO, Logroscino G, Bromfield EB. A clinical score for prognosis of status epilepticus in adults. Neurology 2006; 66: 1736-1738
  • 53 Leitinger M, Holler Y, Kalss G. et al. Epidemiology-based mortality score in status epilepticus (EMSE). Neurocrit Care 2015; 22: 273-282
  • 54 Foreman B, Claassen J, Abou Khaled K. et al. Generalized periodic discharges in the critically ill: A case-control study of 200 patients. Neurology 2012; 79: 1951-1960
  • 55 Rossetti AO, Oddo M. The neuro-ICU patient and electroencephalography paroxysms: If and when to treat. Curr Opin Crit Care 2010; 16: 105-109
  • 56 Logroscino G, Hesdorffer DC, Cascino G. et al. Short-term mortality after a first episode of status epilepticus. Epilepsia 1997; 38: 1344-1349
  • 57 Kilbride RD, Reynolds AS, Szaflarski JP. et al. Clinical outcomes following prolonged refractory status epilepticus (PRSE). Neurocrit Care 2013; 18: 374-385
  • 58 Cooper AD, Britton JW, Rabinstein AA. Functional and cognitive outcome in prolonged refractory status epilepticus. Arch Neurol 2009; 66: 1505-1509
  • 59 Bausell R, Svoronos A, Lennihan L. et al. Recovery after severe refractory status epilepticus and 4 months of coma. Neurology 2011; 77: 1494-1495